Mr. Peter Whitehead reports

LIGHT AI APPOINTS JOHN TSE AS VICE PRESIDENT, COMMERCIAL DEVELOPMENT

Light AI Inc. has appointed John Tse as vice-president, commercial development, effective immediately.

"I am thrilled to welcome John to our team. He brings extensive knowledge of our market and the commercialization of game-changing initiatives," said Peter Whitehead, chief executive officer of Light AI. "With his deep connections to health care leaders in Canada and the USA, both in the industry and government sectors, John will be a tremendous asset to our organization."

Recognized health care industry leader

Mr. Tse has 30 years of senior corporate management and executive leadership with London Drugs, including vice-president, pharmacy and cosmetics, where he was a key member of its executive team advanced the company to be one of the most recognized drugstore chains in Canada and within the top 20 drugstore chains in North America.

With advancements in health care and increasing complexity in treatment options, front-line practitioners need assistance to deliver the right care to the right patients at the right time with a void in the health care technology space. Mr. Tse, a licensed pharmacist, embarked, in 2018, on an entrepreneurial path founding a bioinformatics/pharmacological health care company to identify and market innovative leading health care technology solutions.

"I am excited to join Light AI at this important juncture as the company transitions into commercialization of its leading AI [artificial intelligence] health diagnostic and wellness solutions," said Mr. Tse. "I have been monitoring Light AI's research progress over the past several years and am very impressed with its AI-powered medical condition diagnostic software application delivered via a mobile phone commencing with addressing Strep A infections. Light AI is well positioned to capitalize on a paradigm shift with its disruptive impactful product offering commencing with its consumer-oriented wellness app in Q3 2025."

Mr. Tse has been honoured and nationally recognized for his outstanding contributions in supporting the development and excellence of pharmacy education at the university level; advancing the standards of health care delivery; providing an optimal environment for education and training for pharmacy staff to advance the standards of health care delivery; promoting pharmacy as a community resource in the provision of pharmacy services; and bringing the attention of government and industry partners as to the valuable contributions of community pharmacy. He was the recipient of the Canadian national Len Marks Pharmacy Advance Award in 2017 and the British Columbia Pharmacy Association's Lifetime Achievement Award, which recognizes and honours pharmacists who have made significant, continuing contributions to the pharmacy profession and its members in British Columbia, demonstrating a commitment to leadership and advancement.

Share contractual resale restriction commencement date corrected to Jan. 8, 2025

The company also announced that the contractual resale restrictions of certain common shares issued upon the completion of the business combination completed on Dec. 13, 2024, have been corrected from Dec. 13, 2024, to the date upon which the common shares of the company commenced trading on the Cboe CA Exchange, being Jan. 8, 2025, with the related contractual resale restriction dates adjusted accordingly.

About Light AI Inc.

Light AI is a technology company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform that represents the next generation of patient management: It applies AI algorithms to smart phone images -- starting with images of Strep A -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind; its hardware platform is the 4.5 billion smart phones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving health care delivery worldwide. Its cutting-edge AI-powered technology offers rapid, accurate and cost-effective diagnostic tools designed to address critical health care challenges.

In pre-FDA (U.S. Food and Drug Administration) validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus (GAS). The algorithm achieved a 96.57-per-cent accuracy rate and attained a negative predictive value of 100 per cent, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.